Bladder Cancer, 1st Edition

  • Ja Hyeon Ku
  • Published By:
  • ISBN-10: 0128099402
  • ISBN-13: 9780128099407
  • DDC: 616.99462
  • Grade Level Range: College Freshman - College Senior
  • 724 Pages | eBook
  • Original Copyright 2018 | Published/Released April 2018
  • This publication's content originally published in print form: 2018

  • Price:  Sign in for price



This text is designed for researchers and clinicians involved in urologic practice, including urologists, medical oncologists, pathologists and radiologists. It provides comprehensive guidance for treating and understanding bladder cancer and serves as an up-to-date reference reflecting evidence-based research. The biological behavior of this disease entity shows a heterogeneous pattern with diverse morbidity and mortality depending on a variety of factors, such as tumor characteristics (tumor stage, grade, size, number, shape, and histologic subtypes) and applied treatment modalities (surgery or non-surgical management).

Table of Contents

Front Cover.
Half Title Page.
Title Page.
Copyright Page.
List of Contributors.
About the Editor.
Epidemiology, Etiology, and Pathophysiology.
1: Epidemiology.
2: Etiology (Risk Factors for Bladder Cancer).
3: Pathophysiology of Bladder Cancer.
4: Symptoms.
5: Physical Examination.
6: Urine Cytology and Urinary Biomarkers.
7: Cystoscopy.
8: Bladder Cancer: Imaging.
9: Transurethral Resection of Bladder Tumors.
10: Recent Technological Advances in Cystoscopy for the Detection of Bladder Cancer.
Pathology and Staging.
11: Histological Classification of Bladder Tumors.
12: Tumor, Nodes, Metastases (TNM) Classification System for Bladder Cancer.
Treatment for Nonmuscle Invasive Bladder Cancer (NMIBC).
13: Risk Factors for Recurrence and Progression of Nonmuscle Invasive Bladder Cancer.
14: Treatment for TaT1 Tumors.
15: Treatment for Carcinoma In Situ.
16: Treatment for T1G3 Tumor.
17: Single, Immediate, Postoperative Intravesical Chemotherapy.
18: Second Transurethral Resection of Bladder Cancer.
19: Intravesical Chemotherapy.
20: Immunotherapy: Bacille Calmette–Guérin.
21: Treatment of Failure of Intravesical Therapy.
Treatment for Muscle-Invasive Bladder Cancer (MIBC).
22: Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer.
23: Radical Cystectomy (RC) with Urinary Diversion.
24: Open Techniques and Extent (Including Pelvic Lymphadenectomy).
25: Morbidity, Mortality, and Survival for Radical Cystectomy.
26: Adjuvant Chemotherapy.
27: Bladder-Sparing Treatments.
28: Quality of Life in Bladder Cancer Patients.
Chemotherapy for Metastatic Bladder Cancer.
Follow-Up (Surveillance).
29: Surveillance for Non-Muscle-Invasive Bladder Cancer.
30: The Surveillance for Muscle-Invasive Bladder Cancer (MIBC).
31: Novel and Emerging Surveillance Markers for Bladder Cancer.
Future Perspective in Bladder Cancer.
32: Microbiome.
33: Genetic Testing, Genetic Variation, and Genetic Susceptibility.
34: CRISPR-Genome Editing.
35: Personalized Medicine.